🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Needham reiterates Buy on Lucid Diagnostics following investor day

Published 2023-12-14, 09:44 a/m
© Reuters.
LUCD
-

Needham reiterated a Buy rating, and 12-month price target of $2.50, on Lucid Diagnostics (LUCD) after attending the company’s investor day event on Tuesday.

Needham attended Lucid’s investor day meeting on New York Tuesday where the medical company outlined their operating model and strategy to commercialize its EsoGuard test for esophageal pre-cancer/Barrett's Esophagus (BE) in high-risk patients.

LUCD invited two gastroenterologists to share their insights on EsoGuard. Both experts on the panel emphasized that EsoGuard effectively fulfills an essential gap in diagnosing Barrett's Esophagus (BE) or pre-cancerous conditions.

The experts highlighted that instead of cannibalizing their practices and procedure volumes, the adoption of EsoGuard has led to their expansion. One expert pointed out that given the availability and success rates of BE treatments (including RF ablation), he now feels compelled to screen all high-risk patients using EsoGuard. He further mentioned that none of the patients he diagnosed and treated for Barrett's Esophagus have gone on to develop esophageal cancer.

Management went on to discuss potential financial scenarios to illustrate the effects of enhanced revenue realization and test volume expansion.

According to management's estimations, by maintaining operating expenses and test volume at a constant level while increasing revenue realization from the current 16% to 90% by the second half of 2025, LUCD anticipated a reduction in its cash burn by 42%.

Furthermore, if test volume continued to grow at a sequential rate of 8.5%, LUCD could achieve a cash flow breakeven point by the conclusion of the second quarter of 2025.

Needham analysts wrote in a note, “We believe that increases in LUCD's revenue realization will be the main driver towards profitability, and we believe that LUCD has made good progress in physician adoption and payor reimbursement to date.”

Shares of LUCD are down 0.73% in pre-market trading Thursday morning.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.